# Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

> **NCT01214837** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 751 (actual)

## Conditions studied

- Meningococcal Disease
- Meningococcal Meningitis

## Interventions

- **BIOLOGICAL:** MenACWY-CRM
- **BIOLOGICAL:** MenACWY-CRM
- **BIOLOGICAL:** Routine Vaccines

## Key facts

- **NCT ID:** NCT01214837
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-04
- **Final completion:** 2012-05
- **Target enrollment:** 751 (ACTUAL)
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01214837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01214837, "Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01214837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*